View Author
patient leukemia myeloid leukemia myeloid study treatment blood therapy trial chemotherapy cytogenetic group cancer outcome induction j clin oncol survival promyelocytic leukemia result mutation response expression phase prognostic abnormality bortezomib marrow relapse factor oncol remission disease promyelocytic analysis cytarabine adult diagnosis randomized blast agent inhibitor number cr rate consolidation management protein flt 3 resistance bene fit allogeneic oncology erasmus mc myeloid leukaemia myeloma table allogeneic hsct cycle karyotype daunorubicin fication 60 years transplantation cytogenetic abnormalities leukaemia syndrome -833 psc -833 aml patients all-trans retinoic acid count cell transplantation regimen research tosedostat level combination br j haematol evidence induction therapy sample
9 Most Recent Publications
|
Therapeutic advances in acute myeloid leukemia
(Article)
Burnett, A.K. Wetzler, M. Löwenberg, B. |
2011-02-10
|
|
Phase I/II clinical study of Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia.
(Article)
Löwenberg, B. Morgan, G. Bone, E. Flores, N. Richardson, A.F. Hooftman, L. Jenkins, C. Davies, F. Ossenkoppele, G.J. Burnett, A.K. Zachée, P. Dührsen, U. Dierickx, D. Müller-Tidow, C. Sonneveld, P. Krug, U. |
2010-10-01
|
|
Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet
(Article)
Döhner, H. Estey, E.H. Lo-Coco, F. Naoe, T. Niederwieser, D. Ossenkoppele, G.J. Sanz, M.A. Sierra, J. Tallman, M.S. Löwenberg, B. Bloomfield, C.D. Amadori, S. Appelbaum, F.R. Büchner, T. Burnett, A.K. Dombret, H. Fenaux, P. Grimwade, D. Larson, R.A. |
2010-01-21
|
|
FLT3 inhibition as a targeted therapy for acute myeloid leukemia
(Article)
Sanz, M.A. Burnett, A.K. Lo-Coco, F. Lowenoerg, B. |
2009-11-01
|
|
Management of acute promyelocytic leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet
(Article)
Sanz, M.A. Grimwade, D. Burnett, A.K. Lo-Coco, F. Tallman, M.S. Löwenberg, B. Fenaux, P. Estey, E.H. Naoe, T. Lengfelder, E. Büchner, T. Döhner, H. |
2009-02-26
|
|
CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age
(Article)
Heuvel-Eibrink, M.M. van den Holt, B. van der Burnett, A.K. Knauf, W.U. Fey, M. Verhoef, G.E.G. Vellenga, E. Ossenkoppele, G.J. Löwenberg, B. Sonneveld, P. |
2007-05-01
|
|
The emerging role of targeted therapy for hematologic malignancies: Update on bortezomib and tipifarnib
(Article)
Armand, J.-P. Burnett, A.K. Drach, J. Harousseau, J-L. Löwenberg, B. San Miguel, J-F. |
2007-04-16
|
|
Various distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60 years and older express adverse prognostic value: Results from a prospective clinical trial
(Article)
Holt, B. van der Breems, D.A. Beverloo, H.B. Berg, H. van den Burnett, A.K. Sonneveld, P. Löwenberg, B. |
2007-01-01
|
|
The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis
(Article)
Holt, B. van der Verhoef, G.E.G. Knauf, W.U. Dugan, M. Shepherd, J. Piccaluga, P.P. Ossenkoppele, G.J. Vellenga, E. Ferrant, A. Fey, M.F. Crump, M. Theobald, M. Sonneveld, P. Selleslag, D. Löwenberg, B. Burnett, A.K. |
2005-01-01
|
